Kamala Thriemer

Acceptability and feasibility of glucose-6-phosphate dehydrogenase (G6PD) testing using SD Biosensor by village malaria workers in Cambodia: a qualitative study Introduction Plasmodium vivax is the predominant cause of malaria in the Greater Mekong Subregion. To ensure safe treatment with primaquine, point-of-care glucose-6-phosphate dehydrogenase (G6PD) test...

New in BMJ Global Health: Can village malaria workers in Cambodia safely use the SD Biosensor for G6PD testing?

We explored the acceptability and feasibility of community-based testing to support radical cure for P. vivax malaria.
🔗 gh.bmj.com/content/10/6...

#Malaria #Vivax #G6PD #GlobalHealth

A key component of malaria elimination strategies is robust surveillance which is essential for monitoring trends in case numbers, guiding public health interventions, and prioritizing resource allocation.
shorturl.at/ODNBt

#Malaria #GlobalHealth #MalariaElimination

Massive thanks to the teams in Cambodia and Ethiopia and to collaborators across the globe!

Suggestions include:
🔹 Involving Community health workers, facility staff & local leaders in sensitization
🔹 Integrating outreach into existing community activities
🔹 Joint training sessions to reinforce partnerships
🔹 Open communication with patients to strengthen patient agency

In both settings: Collaboration across all health system levels is crucial for effective follow-up care.
How can we strengthen this collaboration?
#HealthSystems #ImplementationScience

👥 Focus groups in Cambodia & Ethiopia helped co-design locally appropriate Day 3 follow-up models:
📍 Cambodia: community-based visits prioritising symptom assessment & proximity to patients
📍 Ethiopia: continuity of care most important & and tiered approach required
#CommunityEngagement

Led by two brilliant @menziesresearch.bsky.social PhD students, @cassidyseyoum.bsky.social and Muthoni Mwaura 💪
This work highlights the power of co-design in global health research. #Malaria #PhDResearch

Co-design of a routine clinical review to improve the safety of high dose radical cure treatment for Plasmodium vivax malaria: findings from Cambodia and Ethiopia - Malaria Journal Background Low dose primaquine regimens are widely used to treat Plasmodium vivax malaria, but they have limited efficacy and effectiveness. Short courses with higher daily doses as well as single dos...

🎉 New publication out in Malaria Journal!
This study explores how a simple Day 3 clinical review can help improve the safety of high-dose radical cure treatments for Plasmodium vivax malaria.
📖 Read here: link.springer.com/article/10.1...

Great so see such so many people come to the @menziesresearch.bsky.social open day! Thanks to everyone from the malaria team for such a great interactive display!

🔗 Full article 👉 gh.bmj.com/content/10/5...

#Malaria #VivaxMalaria #Indonesia #HealthSystems #Surveillance #BMJGlobalHealth #PublicHealth #MenziesResearch #PhDResearch #HealthPolicy #GlobalHealth

👏 This work was led by @menziesresearch.bsky.social PhD student Ery Setiawan. Thanks to our co-authors @devinefy.bsky.social, @ricprice99.bsky.social, @kevinbaird.bsky.social and Helen Prameswary.

Integrating NHI data into routine malaria surveillance to give the Ministry of Health more detailed insights to target malaria control & elimination more effectively.

📆 Nearly 5% of malaria patients re-presented to hospital within 30 days of their first treatment.
⚠️ Over 50% of these returns were due to new malaria episodes showing the importance of providing highly effective treatment AND ensuring patients complete the full course.

💉 The acute costs of inpatient care were closely linked to:
1. Severity of malaria disease
2. Presence of additional (non-malaria) diagnoses
3. Duration of hospital stay

What did we find?
🏥 Inpatient malaria treatment costs were 10x higher than outpatient costs at hospital level.
🦠 P. vivax patients had higher re-presentation costs than P. falciparum patients.

📢 New study out in BMJ Global Health: We analysed Indonesia’s National Health Insurance (NHI) claims to better understand the health & financial burden of malaria. A step towards improving malaria control & elimination efforts.

Excited about @nhmrc.bsky.social funding!

We’re testing a simplified 3-day primaquine regimen for P. vivax malaria.

Thanks @menziesresearch.bsky.social and all partners!

Shout-out to Brioni Moore + Laurens Manning for the idea + early data 💪

#Malaria #ClinicalTrials #GlobalHealth #Research

Prof Kamala Thriemer has been awarded a 2024 NHMRC Clinical Trials and Cohort Studies Grant for the project “An ultra-short course of primaquine for the radical cure of vivax malaria”—a major step forward in the global fight against #malaria. Read about the grant: acreme.edu.au/announcement...

Big thanks to our amazing teams in Cambodia, Ethiopia, Pakistan & Indonesia—and to every participant who shared their views with us. 🙏💛
@menziesresearch.bsky.social @acreme.bsky.social

#GlobalHealth #ResearchEthics #ParticipantVoices

Now we're taking the next step:
🛠️ Putting these findings into practice and co-designing dissemination strategies that reflect what participants actually want.

Some participants wanted community meetings.
Others preferred 1-on-1 conversations with health workers.
And in some places—people didn’t want to receive results at all.

There’s no one-size-fits-all.

New paper out! 📄 We asked malaria trial participants in Cambodia, Ethiopia, Indonesia and Pakistan how they want to receive study results.

💬 The answer? It depends.
🔗 doi.org/10.1017/cts....

Fantastic couple if days in Karachi and very delighted to present and discuss results from the EFFORT study with national and provincial stakeholders to improve case management for vivax malaria. @menziesresearch.bsky.social @acreme.bsky.social @mmv.org

Delighted to present and disucss results from the EFFORT study with stakeholders in Cambodia to improve case management for vivax malaria. @menziesresearch.bsky.social @acreme.bsky.social

Looking forward to the next ICPvR in Peru 🇵🇪 10/10

Congrats to Angela and Muthoni for winning the poster awards! 9/10

And last but not least, using qualitative work by Muthoni Mwaura to explore how a clinical follow up visit for vivax malaria patients could be implemented into routine care 8/10

Sarah Cassidy-Seyoum presenting her work on assessing the implementation of the G6PD biosensor in Cambodia 7/10

Anjana Rai and Angela Rumaseb presenting their posters on on genetic evidence of cross border transmission and surveillance of imported cases 6/10

Ashley Osborne presenting work on deciphering hidden reservoirs of vovax malaria in Ethiopia using identity-by-decent and time-to-event data 5/10